# Next-Generation Sequencing * **Definition:** Next-Generation Sequencing (NGS) refers to advanced sequencing technologies that allow for the rapid and cost-effective sequencing of large amounts of DNA or RNA, enabling comprehensive genomic analysis, including whole-genome sequencing, targeted sequencing, and transcriptome sequencing, which are widely used in healthcare for diagnostics, personalized medicine, and research. * **Taxonomy:** Healthcare Topics / Next-Generation Sequencing ## News * Selected news on the topic of **Next-Generation Sequencing**, for healthcare technology leaders * 3.6K news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 5/24/2025 | [**Healthcare Provider Population Health Management Platforms Market Size 2025 - LinkedIn**](https://www.linkedin.com/pulse/healthcare-provider-population-health-management-lnpkf/) | [[Linkedin]] | | 5/9/2025 | [**Precision Medicine Market Analysis Report 2024-2030: Bristol-Myers Squibb, Illumina ...**](https://finance.yahoo.com/news/precision-medicine-market-analysis-report-131300143.html) | [[Yahoo Finance]] | | 3/27/2025 | [**Single-cell Analysis Market Surges to USD 5.4 Billion by 2033, Propelled by 9.5AGR**](https://finance.yahoo.com/news/single-cell-analysis-market-surges-144500219.html) | [[Yahoo Finance]] | | 1/31/2025 | [**Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial ...**](https://finance.yahoo.com/news/interpace-biosciences-announces-preliminary-full-133000118.html) | [[Yahoo Finance]] | | 1/30/2025 | [**Genomics Market to Grow by USD 5.21 Billion (2024-2028), Boosted by Rising Investments ...**](https://finance.yahoo.com/news/genomics-market-grow-usd-5-023900667.html) | [[Yahoo Finance]] | | 1/28/2025 | [**Next-generation Sequencing (NGS) Market to Hit USD 22.38 Billion by 2029 with 11.0AGR**](https://www.prnewswire.com/news-releases/next-generation-sequencing-ngs-market-to-hit-usd-22-38-billion-by-2029-with-11-0-cagr--marketsandmarkets-302361621.html) | [[PR Newswire]] | | 1/28/2025 | [**Next-generation Sequencing (NGS) Market to Hit USD 22.38 Billion by 2029 with 11.0AGR - MarketsandMarkets™**](https://finance.yahoo.com/news/next-generation-sequencing-ngs-market-150100124.html) | [[Yahoo Finance]] | | 1/23/2025 | [**Next-Generation Sequencing Services Market Poised for Remarkable Growth - Yahoo Finance**](https://finance.yahoo.com/news/next-generation-sequencing-services-market-151500905.html) | [[Yahoo Finance]] | | 1/23/2025 | [**Next-Generation Sequencing Services Market Poised for Remarkable Growth - PR Newswire**](https://www.prnewswire.com/news-releases/next-generation-sequencing-services-market-poised-for-remarkable-growth-projected-to-increase-from-7-billion-in-2024-to-15-billion-by-2031---market-research-intellect-302358332.html) | [[PR Newswire]] | | 12/31/2024 | [**Precision Medicine Software Market Focused Insights 2024-2029, with Key Player Profiles of ...**](https://www.businesswire.com/news/home/20241231013633/en/Precision-Medicine-Software-Market-Focused-Insights-2024-2029-with-Key-Player-Profiles-of-Syapse-AccessDX-Laboratory-Fabric-Genomics-Foundation-Medicine-Intel-and-IBM---ResearchAndMarkets.com) | [[Business Wire]] | | 12/31/2024 | [**Precision Medicine Software Market Focused Insights 2024-2029, with Key Player Profiles of Syapse, AccessDX Laboratory, Fabric Genomics, Foundation Medicine, Intel and IBM - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241231013633/en/Precision-Medicine-Software-Market-Focused-Insights-2024-2029-with-Key-Player-Profiles-of-Syapse-AccessDX-Laboratory-Fabric-Genomics-Foundation-Medicine-Intel-and-IBM---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-Q-tiwWZwkcswR1UZtV7eGe24xL9TZOyQUMS3J72mJlQ7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LOzmn6JePCpHPCiYGaEx4DL1Rq8pNwkf3AarimpDzQGuQ==) | [[Business Wire]] | | 12/31/2024 | [**Precision Medicine Software Market Focused Insights 2024-2029, with Key Player Profiles of Syapse, AccessDX Laboratory, Fabric Genomics, Foundation Medicine, Intel and IBM - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241231013633/en/Precision-Medicine-Software-Market-Focused-Insights-2024-2029-with-Key-Player-Profiles-of-Syapse-AccessDX-Laboratory-Fabric-Genomics-Foundation-Medicine-Intel-and-IBM---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 12/30/2024 | [**Precision Medicine Software Research Analysis Report 2024-2030: Increasing Adoption of Genomic Data Analysis Software Spurs Growth, Integration of Multi-Omics Data Strengthens the Business Case - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241230952002/en/Precision-Medicine-Software-Research-Analysis-Report-2024-2030-Increasing-Adoption-of-Genomic-Data-Analysis-Software-Spurs-Growth-Integration-of-Multi-Omics-Data-Strengthens-the-Business-Case---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-Q-tiwWZwkcswR1UZtV7eGe24xL9TZOyQUMS3J72mJlQ7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LOzmn6JePCpHPCiYGaEx4DL1Rq8pNwkf3AarimpDzQGuQ==) | [[Business Wire]] | | 12/30/2024 | [**Precision Medicine Software Research Analysis Report 2024-2030: Increasing Adoption of Genomic Data Analysis Software Spurs Growth, Integration of Multi-Omics Data Strengthens the Business Case - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241230952002/en/Precision-Medicine-Software-Research-Analysis-Report-2024-2030-Increasing-Adoption-of-Genomic-Data-Analysis-Software-Spurs-Growth-Integration-of-Multi-Omics-Data-Strengthens-the-Business-Case---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 12/24/2024 | [**Precision Medicine Software Research Analysis Report 2024: Market to Reach $4.4 Billion ...**](https://finance.yahoo.com/news/precision-medicine-software-research-analysis-132900381.html) | [[Yahoo Finance]] | | 12/2/2024 | [**Next Generation Cancer Diagnostics Business Research Report 2024-2030: Technological Advancements in ctDNA, CTC, and Circulating miRNA Testing Propel Market Growth - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241202011489/en/Next-Generation-Cancer-Diagnostics-Business-Research-Report-2024-2030-Technological-Advancements-in-ctDNA-CTC-and-Circulating-miRNA-Testing-Propel-Market-Growth---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 11/25/2024 | [**Clinical Next-Generation Sequencing Market Analysis, Trends and Dynamic Demand by Forecast 2024 to 2033**](http://prsync.com/stringent-datalytics/clinical-next-generation-sequencing-market-analysis-trends-and-dynamic-demand-by-forecast--to--4452625/) | [[PRSync]] | | 11/25/2024 | [**Digi-Tech Pharma & AI Conference 2025: AI and Genomics Take Center Stage (London ...**](https://www.marketwatch.com/press-release/digi-tech-pharma-ai-conference-2025-ai-and-genomics-take-center-stage-london-united-kingdom-may-28-29-2025-researchandmarkets-com-2a20b074) | [[MarketWatch]] | | 11/19/2024 | [**Next-Generation Sequencing Industry Research Outlook 2024-2031: Increasing Application of NGS in Personalized Medicine Generating Growth Opportunities for Market Players - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241119182227/en/Next-Generation-Sequencing-Industry-Research-Outlook-2024-2031-Increasing-Application-of-NGS-in-Personalized-Medicine-Generating-Growth-Opportunities-for-Market-Players---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 11/19/2024 | [**Next-Generation Sequencing Industry Research Outlook 2024-2031: Increasing Application ...**](https://www.businesswire.com/news/home/20241119182227/en/Next-Generation-Sequencing-Industry-Research-Outlook-2024-2031-Increasing-Application-of-NGS-in-Personalized-Medicine-Generating-Growth-Opportunities-for-Market-Players---ResearchAndMarkets.com) | [[Business Wire]] | | 11/14/2024 | [**Bumrungrad International Hospital Partners with Golden Helix to Advance Genomics for Cancer and Hereditary Disease Initiatives**](https://www.prnewswire.com/news-releases/bumrungrad-international-hospital-partners-with-golden-helix-to-advance-genomics-for-cancer-and-hereditary-disease-initiatives-302304751.html) | [[PR Newswire]] | | 11/8/2024 | [**AI-driven precision healthcare is here - what you need to know**](https://www.healthcareitnews.com/news/ai-driven-precision-healthcare-here-what-you-need-know) | [[Healthcare IT News]] | | 11/7/2024 | [**Next-Generation Sequencing (NGS) Services Market is expected to generate a revenue of ...**](https://www.prnewswire.com/news-releases/next-generation-sequencing-ngs-services-market-is-expected-to-generate-a-revenue-of-usd-18-35-billion-by-2031--globally-at-21-25-cagr-verified-market-research-302298672.html) | [[PR Newswire]] | | 11/7/2024 | [**New Tech Trends in Healthcare for 2025**](https://healthcareguys.com/2024/11/07/new-tech-trends-in-healthcare-for-2025/) | [[The Healthcare Guys]] | | 6/12/2024 | [**Clinical Oncology Next-Generation Sequencing Market Size & Share to Surpass USD 35.42 Billion by 2030.**](http://prsync.com/maximize-market-research-company/clinical-oncology-next-generation-sequencing-market-size--share-to-surpass-usd--billion-by--4171710/) | [[PRSync]] | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **ERS Genomics**: A company that holds a significant patent portfolio for CRISPR/Cas9 technology, enhancing next-generation sequencing capabilities. - **10X Genomics**: A biotechnology company specializing in genomic analysis and next-generation sequencing technologies. - **Illumina**: A leader in next-generation sequencing technology, providing a range of products for genomic analysis. - **Complete Genomics**: A company expanding its manufacturing capabilities in the U.S. to enhance its sequencing technology offerings. - **Agilent Technologies, Inc.**: A key provider of advanced genomic solutions, including next-generation sequencing technologies. - **Illumina, Inc.**: A leading company in next-generation sequencing technology, providing tools and services for genomic analysis. - **OneCell Diagnostics**: A genomics-based precision oncology company utilizing next-generation sequencing for cancer diagnostics. - **Oxford Nanopore Technologies**: A key player in the NGS market, recognized for its advancements in sequencing technology. - **Clear Labs**: Focuses on enhancing NGS platforms for diagnostics, aiming to simplify sequencing workflows. - **QIAGEN**: A significant contributor to the NGS services market, focusing on precision medicine and genomics. - **Inocras Inc.**: A company offering whole genome sequencing services using the UG 100 sequencer from Ultima Genomics. - **SOPHiA GENETICS**: A company that launched the OncoPortal™ Mutation Tracker for monitoring minimal residual disease in oncology using next-generation sequencing. - **Foresee Genomics**: A startup focused on democratizing access to genomic technologies, recently closing a $1.3 million funding round. - **BostonGene**: A company collaborating with the Icahn School of Medicine to conduct precision medicine studies using AI-powered NGS. - **Foundation Medicine**: Provides genomic profiling solutions to inform personalized treatment strategies. - **Thermo Fisher Scientific**: Offers analytical tools and laboratory equipment, contributing to advancements in NGS and molecular diagnostics. - **Syapse**: Offers precision medicine software solutions for genomics analysis and clinical decision support. ### Partnerships and Collaborations - **Inocras and Ultima Genomics**: Partnering to enhance whole genome sequencing services with the UG 100 sequencer. - **ERS Genomics and Jumpcode Genomics**: A non-exclusive license agreement allowing Jumpcode to utilize ERS's CRISPR/Cas9 patent portfolio to improve sequencing technology. - **Thermo Fisher Scientific and Pfizer**: Collaborating to enhance NGS testing capabilities. - **DNAnexus and Discovery Life Sciences**: Partnership aimed at improving precision health data analysis. - **Clear Labs and Strategic Investors**: Secured $30 million in Series D financing to enhance NGS platforms. - **BostonGene and Icahn School of Medicine**: Collaborating on a precision medicine clinical study for multiple myeloma using AI-powered NGS. - **Golden Helix and Danish healthcare regions**: A multi-year agreement to enhance genomic capabilities in laboratories, focusing on cancer and hereditary disease diagnostics. - **Guardant Health and ConcertAI**: Collaborating to provide biopharmaceutical companies with access to a unique multi-modal real-world data solution integrating patient electronic medical records with genomic profiling. - **Bumrungrad International Hospital and Golden Helix**: A collaboration aimed at enhancing genomics initiatives for cancer and hereditary disease diagnostics. - **OneCell Diagnostics and Harvard Medical School/Stanford University**: Strategic partnerships aimed at enhancing cancer management and diagnostics through advanced testing. - **Genoks and Velsera**: This partnership aims to integrate Velsera's Clinical Genomics Workspace into Genoks' cancer diagnostic services, enhancing accuracy in cancer detection. - **Mayo Clinic, Microsoft Research, and Cerebras Systems**: A partnership focused on developing AI models that integrate genomic sequencing data and radiology images to improve diagnostic accuracy. - **GE HealthCare and Emory University**: Working together on predictive tools for forecasting cancer recurrence. - **GE HealthCare and Amazon Web Services**: Collaborating to develop AI models using anonymized X-ray images to automate diagnostics. ### Innovations, Trends, and Initiatives - **Next-Generation Sequencing (NGS)**: A transformative technology enabling rapid and cost-effective sequencing of DNA, facilitating personalized medicine and precision oncology. - **Commercial Sequencing Services**: Expected to dominate the NGS market, driven by demand for quick results and cost-effectiveness. - **Next-Generation Cancer Diagnostics (NGCD)**: Utilizes advanced technologies like liquid biopsy and NGS to provide detailed molecular insights for personalized cancer treatment. - **Emerging Sequencing Technologies**: Nanopore sequencing provides portable and real-time capabilities for diagnostics. - **Clinical Applications**: NGS is increasingly used in oncology, genetic disease screening, and drug discovery, providing actionable intelligence for healthcare leaders. - **Decentralized Sequencing Systems**: Innovations in automation and miniaturization improving access to precision oncology and enabling faster diagnostic decisions. - **Decentralized NGS Technologies**: Emerging trend to improve clinical trial efficiency by enabling testing closer to patients. - **Advancements in NGS Technologies**: Improved accuracy, efficiency, and reduced costs are driving market growth. - **Cost Reduction**: The cost of sequencing a human genome has decreased significantly, from $29,092 in 2010 to $562 in 2021, facilitating wider adoption of NGS services. - **Multi-Omic Approaches**: Emerging trend in genomics that combines multiple types of biological data for comprehensive insights into diseases. - **AI Integration**: The integration of AI with NGS is enhancing data analysis efficiency and enabling personalized treatment plans. - **Integration of AI with Genomics**: Enhancing the analysis of large genomic datasets to identify patterns for breakthroughs in disease prediction and treatment. - **Liquid Biopsy Tests**: Labcorp's PGDx elio plasma focus Dx allows genomic profiling from blood samples, improving precision oncology. - **Integration of AI and Machine Learning**: Enhancing genomic data analysis and enabling personalized treatment pathways. - **Market Growth**: The NGS market is projected to grow from $13.0 billion in 2022 to $27.0 billion by 2027, driven by advancements in technology and increasing cancer rates. - **OncoPortal™ Mutation Tracker**: A tool for tracking genomic variants over time, enhancing treatment resistance detection and patient stratification. - **AI and Machine Learning in Genomics**: Integration of AI in genomic data analysis is enhancing the identification of genetic markers and improving treatment predictions. - **Platforma.bio SDK**: An innovative software development kit by MiLaboratories that allows biologists to analyze NGS data independently, reducing reliance on bioinformaticians. ### Challenges and Concerns - **High Costs of Genotyping Technologies**: Despite advancements, the costs associated with next-generation sequencing technologies remain a barrier to widespread adoption. - **Need for Extensive Training**: Healthcare professionals require training to effectively utilize NGS technologies. - **Cost and Accessibility**: Despite declining sequencing costs, access to NGS technologies remains a concern for smaller laboratories. - **Skilled Workforce Shortage**: The NGS services market is hindered by a shortage of skilled professionals necessary for advanced genomic analysis. - **Data Analysis Bottlenecks**: The reliance on bioinformaticians for NGS data analysis can create bottlenecks in research progress. - **High Implementation Costs**: Hinders widespread adoption of NGS technologies, especially in smaller healthcare institutions. - **Regulatory Compliance**: Ensuring compliance with regulatory requirements for new diagnostic products and genomic testing. - **Budget Constraints**: Developing countries face challenges in adopting advanced NGS technologies due to budget limitations. - **Need for Trained Professionals**: The complexity of genomic data interpretation necessitates a workforce skilled in bioinformatics and genomics. - **Data Security and Standardization**: Concerns regarding the handling and protection of genomic data. - **Inadequate Medical Reimbursements**: Challenges in reimbursement policies may hinder the expansion of NGS technologies in clinical settings. - **Regulatory Hurdles**: Lengthy approval processes and compliance with safety standards pose obstacles for new genomic products entering the market. - **Access Disparities**: Significant barriers to genomic testing and tumor biopsies, particularly in underserved communities, limiting access to precision medicine. - **High Costs of Testing**: The expense associated with advanced genetic testing can limit accessibility for patients, particularly in low-resource settings. - **Data Privacy and Security**: Concerns regarding the handling of sensitive genomic data, which could hinder the growth of precision medicine. - **Data Integration**: The need for effective integration of genomic data into electronic health records and clinical workflows. - **Data Security and Privacy**: Concerns regarding the security of genomic data and compliance with privacy regulations are significant challenges in the integration of AI and genomics. - **Lack of Diverse Genomic Data**: Insufficient genomic data from African populations limits the effectiveness of diagnostics and highlights the need for more research. - **Regulatory Concerns**: There are ongoing regulatory challenges regarding diagnostic testing and ethical issues in prenatal genetic testing. - **Interoperability Issues**: Challenges in integrating various systems and technologies in healthcare settings. ## Related Topics [[Genomic Sequencing]]